SynthesisPloS one2019
Comparison between liver transplantation and resection for hilar cholangiocarcinoma: A systematic review and meta-analysis.
Synthesis in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Can the Limits of Liver Transplantation Be Expanded in Perihilar Cholangiocarcinoma?Journal of gastrointestinal cancer · 2022Pooled it
- Left-side vs. right-side hepatectomy for hilar cholangiocarcinoma: a meta-analysis.World journal of surgical oncology · 2021Pooled it
- Liver resection with and without vascular resection versus transplantation for de novo perihilar cholangiocarcinoma.Hepatology (Baltimore, Md.) · 2026Article
- Current Status of Drug Treatment of Cholangiocarcinoma-Updated Progress and Critical Limitations.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Present and future of liver transplantation for cholangiocellular carcinoma: moving toward personalized multiparametric transplantability patterns.Transplant international : official journal of the European Society for Organ Transplantation · 2026Review
- Implementing Massive Parallel Sequencing into Biliary Samples Obtained through Endoscopic Retrograde Cholangiopancreatography for Diagnosing Malignant Bile Duct Strictures.International journal of molecular sciences · 2024Article
- Treatment of cholangiocarcinoma by pGCsiRNA-vascular endothelial growth factor in vivo.Asian biomedicine : research, reviews and news · 2024Article
- National guidelines for the diagnosis and treatment of hilar cholangiocarcinoma.World journal of gastroenterology · 2024Review
- Review
- Updates and Expert Opinions on Liver Transplantation for Gastrointestinal Malignancies.Medicina (Kaunas, Lithuania) · 2023Review
- Liver transplantation in the management of cholangiocarcinoma: Evolution and contemporary advances.World journal of gastroenterology · 2023Review
- Liver transplantation for cholangiocarcinoma.Clinical liver disease · 2023Article
- New Insights in the Setting of Transplant Oncology.Medicina (Kaunas, Lithuania) · 2023Review
- Surgery.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2023Article
- PRR11 in Malignancies: Biological Activities and Targeted Therapies.Biomolecules · 2022Review
- Current status of liver transplantation for cholangiocarcinoma.World journal of gastrointestinal surgery · 2022Review
- Gemcitabine Plus Cisplatin Versus Non-Gemcitabine and Cisplatin Regimens as Neoadjuvant Treatment for Cholangiocarcinoma Patients Prior to Liver Transplantation: An Institution Experience.Frontiers in oncology · 2022Article
- Moving forward in the treatment of cholangiocarcinoma.World journal of gastrointestinal oncology · 2021Review
- Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis.World journal of gastrointestinal oncology · 2021Review
- Transplant Oncology: An Evolving Field in Cancer Care.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHilar cholangiocarcinoma (hCCA) is a rare and aggressive malignancy with R0 resection being currently the only option for long-term survival. With the improvement in the outcomes of liver transplantation (LT), the indications for LT have expanded to include other malignant tumors, such as hCCA. The aim of the present analysis is to demonstrate and critically evaluate the outcomes of LT compared to resection with curative intent in patients with hCCA.
methodsWe systematically searched the literature for articles published up to May 2018. The following algorithm was applied ((hilar cholangiocarcinoma) OR (perihilar cholangiocarcinoma) OR klatskin$ OR (bile duct neoplasm) OR cholangiocarcinoma) AND (transplant$ OR graft$).
resultsNeoadjuvant treatment with chemotherapy and radiation therapy was far more common in the LT group, with very few patients having received preoperative therapy in the resection group (p = 0.0005). Moreover, length of hospital stay was shorter after LT than after resection (p<0.00001). In contrast, no difference was found between the two treatment methods concerning postoperative mortality (p = 0.57). There was a trend towards longer overall survival after LT in comparison with resection. This was not obvious in the first year postoperatively, however, the advantage of LT over resection became obvious at 3 years after the operation (p = 0.02).
conclusionsIn non-disseminated unresectable tumors, LT seems to have a non-inferior survival. In the same patients, neoadjuvant chemoradiotherapy and/or strict selection criteria may contribute to superior survival outcomes compared to curative-intent resection. Due to the scarcity of level 1 evidence, it remains unclear whether LT should be increasingly considered for technically resectable early stage hCCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.